Science and research are the cornerstone of our strategic cooperation. We develop joint R&D projects between scientific teams in Latin America and China, focused on vaccines, diagnostics, natural products and innovative technologies applied to the biopharmaceutical sector.
Finlay Vaccine Institute (Cuba) + Hebei BioBridge Medical Technology (HBMT)
The world's first bivalent vaccine against meningococcal serogroups B and C, developed by the Finlay Institute. Pioneering outer membrane vesicle (OMV) technology, with demonstrated clinical efficacy of 83% and a >95% reduction in disease among vaccinated populations. Registered in multiple countries, with more than 60 million doses administered and strong international scientific backing.
Strategic alliances for registration and commercialization in China, technology transfer, local production via CMO/CDMO, new developments, technology upgrades and expansion into new Asian markets.
CIE / Digifluidic
A microfluidics-based biomedical diagnostics platform, currently in the clinical trial and technical structuring phase. Detailed technical description and objectives available under a confidentiality agreement.
Alliances for technology co-development, investment and scalability, as well as partners for registration and commercialization in China and Latin America.
Center of Molecular Immunology (CIM, Cuba) + Hebei BioBridge Medical Technology (HBMT)
Development of an innovative bispecific molecule that antagonizes the IL-6 pathway and targets the EGFR receptor, focused on the treatment of pancreatic cancer (PDAC) and triple-negative breast cancer. Built on proprietary assets, a platform validated by CIM, and successful regulatory experience in China with Nimotuzumab.
Investment for proof-of-concept studies, lead candidate optimization, preclinical studies and preparation for regulatory filing (IND). Alliances with Chinese CMOs/CDMOs and partners for clinical co-development.
CIDEM (Drug Research and Development Center, Cuba) + Hebei BioBridge Medical Technology (HBMT)
A natural nutritional supplement based on microencapsulated lipid extract of Cucurbita pepo L., rich in antioxidants, fatty acids, vitamins and minerals. Supports prostate health, maintains normal urinary function in adult men, and stimulates osteogenesis, helping prevent tooth decay and demineralization. Safe, non-toxic profile with a 24-month stability.
Strategic alliances for health registration in China, commercialization, distribution, local production through industrial partners, and expansion into Asian markets.
CIDEM (Drug Research and Development Center, Cuba) + Hebei BioBridge Medical Technology (HBMT)
A dermo-regenerating, moisturizing chitosan-based cream with antioxidant activity capable of repairing skin damaged by UV radiation. Stimulates cell regeneration, reorganizes collagen fibers, and softens fine lines. Safe product, free of heavy metals, with rigorous microbiological control and proven stability.
Alliances for health registration in China, commercialization, distribution, local production and expansion into Asian markets.
BioCubaFarma
An artificial-intelligence-based technology platform aimed at optimizing processes within the biopharmaceutical and health sector, currently in the development and structuring phase.
Technology alliances, investment and partners for industrial application in China and Latin America.